Drug Information

Drug General Information
Drug ID
D03ESR
Former ID
DIB008581
Drug Name
Sphingosome Encapsulated Vinorelbine
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 3 [522410]
Company
Hana Biosciences
Target and Pathway
Target(s) Tubulin beta Target Info Modulator [529890]
KEGG Pathway Phagosome
Gap junction
Pathogenic Escherichia coli infection
NetPath Pathway FSH Signaling Pathway
TCR Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Cytoskeletal regulation by Rho GTPase
Huntington disease
Reactome Regulation of PLK1 Activity at G2/M Transition
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Anchoring of the basal body to the plasma membrane
WikiPathways Parkin-Ubiquitin Proteasomal System pathway
Pathogenic Escherichia coli infection
Mitotic G2-G2/M phases
References
Ref 522410ClinicalTrials.gov (NCT00737867) Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 529890Liposomal-encapsulated doxorubicin (Myocet; D-99) and vinorelbine in previously treated metastatic breast cancer patients: a feasibility study. Tumori. 2008 Sep-Oct;94(5):686-90.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.